Analysis of the combined effect of rs699 and rs5051 on angiotensinogen expression and hypertension

RNA is unlocking the ability to develop life‑saving therapies at unprecedented speed. The recent success with baby KJ demonstrates how RNA medicine can move a personalized treatment from diagnosis to clinic in less than a year.

Eclipse Bioinnovations, Inc. (Eclipsebio), the leading partner for RNA-based and RNA-targeting therapeutic development, today announced the launch of its eVERSE™ portfolio of AI-ready datasets. eVERSE is a first-in-class collection of datasets generated from all key aspects of RNA biology that inform therapeutic development from target discovery to drug design.

Artificial intelligence (AI) is transforming how we approach RNA research and drug discovery. In this eBlog we review how data is one of the key pillars for the successful use of AI.

To support researchers as they generate RNA datasets, Eclipsebio is proud to announce the 2025 Data Catalyst Award. Winners of the award will obtain matching funds to cover the cost of generating their control datasets.